Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
May 15, 2005 (Vol. 25, No. 10)

Genome Canada

  • Research descriptions, career opportunities
  • Poor organization
If you want to learn about the primary funding and information source of genomics and proteomics in Canada, head to Genome Canada. What brought me to the site was its clever, descriptive name. What I found when I got there was a not so well-thought out opening page that can best be described in three words-Busy, Busy, Busy. It abounds with calenders, events, pictures, conference information, etc. The trouble is, a little hierarchical design would not only make this look better, it would be a more efficient use of space. There are some gems at the site, but they're hidden amongst the noise. Highlights of Genome Canada include a description of research programs, an extensive Canadian genomics/proteomics directory, a listing of career opportunities, an interesting ethics section, and a general genomics education center.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good

*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »